To evaluate the incidence, risk factors and prognosis for solid tumors after hematopoietic stem cell transplantation (HSCT) in Japan, 809 patients who had received HSCT between 1981 and 2000 were retrospectively analyzed. In all, 19 newly diagnosed secondary cancers were observed. The risk for cancer development was 2.8 times as high as that for expected cases. The cumulative incidence ratios at 5 and 10 years were 1.9 and 4.2%, respectively. The risk was significantly elevated for buccal cavity cancer (standard incidental ratio (SIR), 44.42: 95% confidence interval (CI) 17.86-91.51), esophageal cancer (SIR, 22.36: 95% CI 6.09-57.25), and cervical cancer (SIR, 8.58: 95% CI 1.04-31.01). Of 15 patients who developed solid cancers following allografting, 12 had chronic graftversus-host disease (GVHD), and all 10 patients with squamous cell carcinoma of the buccal cavity or esophagus had chronic GVHD. On multivariate analysis, extensive chronic GVHD and age over 45 years at the time of transplantation were associated with a higher risk for solid cancers. In all, 17 patients received therapy for secondary cancers, nine of whom are still alive and the 5-year probability of survival from the diagnosis is 42.8%. Our data suggest that early detection of secondary cancers is very important in prolonging overall survival.
secondary cancers; solid tumors; chronic graft-versus-host disease Hematopoietic stem cell transplantation (HSCT) is widely used to treat patients with hematologic malignancies and other nonmalignant hematologic disorders. The improvement in survival after HSCT has drawn increased attention to late complications in long-term survivors. The development of second malignancies is recognized as one of the most serious complications in such patients. 1 Second malignancies following HSCT fall into three categories: solid tumors, therapy-related myelodysplastic syndrome/ acute myeloid leukemia (t-MDS/AML), and posttransplant lymphoproliferative disorder. [2] [3] [4] [5] For solid tumors, the incidence in previous reports was found to be 2-6% at 10 years, and 6-13% at 15 years. 1, [6] [7] [8] Although these studies have demonstrated a low but significant risk of a second solid tumor after HSCT, few data exist in Japanese patients with different specific incidence rates for cancers at specific anatomical sites. We undertook a retrospective analysis of 809 Japanese patients who received HSCT, using the Nagoya Blood and Marrow Transplantation Group (NBMTG) database to assess the incidence and risk factor of solid tumors following HSCT. In addition, we present the treatment outcomes of these patients.
Patients and methods

Patients and treatment
A total of 1451 patients who received allogeneic and autologous HSCT at 16 institutes cooperating in the NBMTG between 1981 and 2000 were identified from the computerized NBMTG database, where pretransplant and post-transplant data are consecutively collected and maintained on a regular basis by requesting follow-up information and reporting of events. For each second cancer identified in the database, clinical data including date of diagnosis, type and characteristics of the cancer, method of treatment, and outcome were obtained. Each record and pathology report was reviewed to ensure accuracy of the database, contents, and updated for the current analysis.
Patient characteristics are detailed in Table 1 . Among the 809 patients who survived for at least 1 year after transplantation, the median age at transplantation was 34 years (range, 15-70 years). Allogeneic transplantation was performed in 591 patients, 211 patients received autologous marrow and seven patients received syngeneic donor marrow. In all, 410 patients received donations from an HLA-identical sibling and 31 from other family donors. A total of 150 patients received unrelated donor marrow grafts matched for HLA phenotype. Most of the grafts for allogeneic transplantation were bone marrow. Conditioning regimens for 475 patients consisted of total body irradiation (TBI) combined with cyclophosphamide and/or other drugs. Prophylaxis for graft-versus-host disease (GVHD) consisted mainly of methotrexate plus cyclosporine in 489 patients (82.7% of allogeneic transplants). Acute GVHD (grade II-IV) developed in 106, and chronic GVHD in 263 patients (17.9 and 44.5% of allogeneic transplants), respectively. The median duration of follow-up was 5.3 years (range, 1.0-19.9 years) and 6.6 years for survivors.
Statistical analysis
Standardized incidence ratios (SIRs) were calculated to determine whether the number of patients in our cohort who developed a second cancer after receiving a transplant was excessive. These calculations are based on the ratio of the number of patients who developed subsequent invasive cancers after their transplant (observed number) to the number of people in the general population who would be expected to develop primary invasive cancer (expected number). The latter number was determined as follows: for each patient, the number of person-years at risk was calculated from the date of transplantation until the date of the diagnosis of second cancer, date of the last contact, or death, whichever came first. Age (5 years)-, sex-, and calendar year (5 years)-specific incidence rates for all cancers at specific anatomical sites were applied to the appropriate person-years at risk to compute the expected numbers of cancers. The median year of each 5-year period was chosen to represent the incidence rate of that period. For the last period (from 2000 to 2003), the most recent incidence-rate data available (from the year 1998) were used. Incidence rates for all invasive cancers were obtained from the data base of the Research Group for Populationbased Cancer Registration in Japan. [9] [10] [11] [12] The 95% confidence intervals (CIs) for the SIRs were calculated on the assumption that the observed number of cancers followed a Poisson distribution. 13 Cumulative probabilities for the development of secondary solid tumors were calculated by the Kaplan-Meier method with 95% CI calculated using Greenwood's formula. The log-rank test was used to compare the distributions between groups. The influence of potential risk factors was estimated by the Cox proportional-hazard model. Variables selected were those previously described. A stepwise multivariate approach was used to identify the most important predictor variable with respect to the development of secondary solid tumors. A P-value o0.05, after adjustment for the effects of other variables, was required for inclusion in the model. The Kaplan-Meier method was used to calculate survival probability among patients who developed solid tumors.
Results
Among the 809 patients who underwent stem cell transplantation and survived more than 1 year, 19 new cases of solid cancer were identified ( Table 2) . Seven patients were diagnosed with buccal cavity carcinoma, and the remaining 12 with secondary cancers included three with esophageal, two each with cervix uteri and gastric cancer, and one each with uterine cancer, rectal cancer, colon cancer, breast cancer, and squamous cell carcinoma of unknown origin. The latency period from HSCT to the emergence of a new solid cancer ranged from 12 to 139 months. The cumulative incidence rates at 5 and 10 years after transplantation were 1.9 and 4.2%, respectively ( Figure 1 ). The overall risk of developing new solid cancers had significantly increased, with 19 invasive cancers observed compared with 6.7 cases expected in an age-and sex-matched general population (standard incidental ratio Table 1 Characteristics of patient population [9] [10] [11] [12] On the other hand, the risk of gastric cancer, which is the most common cancer in Japan, had not increased compared with that in the general population (SIR, 1.37: 95% CI 0.17-4.95) ( Table 3) .
As shown in Table 2 , 12 patients had undergone allogeneic transplantation from an HLA-matched sibling, three from an unrelated donor, and four had received autologous marrow. Eight patients received TBI-containing preparative regimens before allogeneic transplant. Remarkably, 12 of 15 allo-grafted patients had developed chronic GVHD, nine of whom had the extensive type. Six patients of those nine were receiving immunosuppressive agents at the time of diagnosis of the new cancer. Squamous cell carcinoma of the buccal cavity or esophagus originated from a site involved with chronic GVHD. Univariate regression analyses were performed for the patients who survived for at least 1 year after transplantation. Potential risk factors were evaluated with adjustments for age, sex, type of transplantation, donor, chronic GVHD, etc. Patients with extensive chronic GVHD aged over 45 years had an elevated risk of all solid cancers. Relative risk (RR) was 2.9 (95% CI 1.1-7.2) and 5.1 (95% CI 2.0-12.6), respectively. On multivariate analysis, age, sex, TBI, pretransplant radiotherapy, acute GVHD, and chronic extensive GVHD were added to the Cox proportionalhazard model. Two independent risk factors, that is, extensive chronic GVHD (RR ¼ 2.9: 95% CI 1.1-7.8, P ¼ 0.0352) and age over 45 years (RR ¼ 5.5: 95% CI 1.9-13.8, P ¼ 0.0011), were identified.
Of the 19 patients with new cancers, 17 received various therapies for secondary cancers (Table 2) . Surgery was performed on 12 patients, of which eight operations were curative. All of those who received a curative operation survived more than a year from diagnosis (range 12-115 months). Only one out of three patients treated with chemotherapy and radiotherapy survived about 3 years from diagnosis. Nine out of 19 patients are still alive with no signs of tumor regrowth. The remaining 10 have died from secondary cancers. Finally, the probability of a 5-year survival of patients from their diagnosis of secondary cancers is 42.8% (Figure 2 ).
Discussion
Among the 809 adult patients who received HSCT by the Nagoya Blood and Marrow Transplantation Group 2% at 10 years after transplantation. The overall incidence is 2.8-fold higher than that expected in the general population. This analysis represents one of the largest surveys in Japan. In our cohort of patients, secondary hematological malignancies such as Epstein-Barr virus-associated lymphoma, leukemia, and MDS were excluded, since the spectrum of neoplasms varies with the time after transplantation. 4, 14, 15 Hematologic malignancies generally develop in the early phase following transplantation. 5 On the other hand, solid cancers have a longer latency period. 1, 6 Therefore, this figure certainly represents a significant risk to long-term survival among adult patients undergoing HSCT. The RR obtained from our analysis could be an underestimate of the true risk since the median follow-up duration of 5.3 years is relatively short. In contrast to the other studies, the cumulative incidence of developing a solid cancer plateaued with a relatively short latency. Although this is mainly a consequence of the short follow-up and of the fact that the peak incidence of solid cancers had not been reached, the difference in the spectrum and pathogenesis of secondary cancer may also be a factor.
Potential risk factors associated with the development of secondary cancers following HSCT have been described previously. 1, 6, [16] [17] [18] These include TBI as part of the preconditioning regimen, the use of immunosuppressive agents, and the occurrence of acute or chronic GVHD. In our study, two independent risk factors were identified, namely, subjects with extensive-type chronic GVHD and those above 45 years of age at transplant. TBI containing preconditioning was not a statistically significant risk factor. Radiogenic cancers generally have a long latent period, and the risk of such cancers is frequently high among patients undergoing irradiation at a young age. 17, 19 Certain tumor types such as those of the brain, thyroid, salivary gland, and bone connective tissue occur in association with radiation exposure. [20] [21] [22] [23] [24] These tumors were not observed in our study, which included only adult patients. In two large studies, brain and thyroid cancers accounted for the increased risk of TBI in their cohorts of children. 1, 6 The risk of radiogenic cancers may decline with age. According to the previous report, the cumulative incidence of second cancer patients who had received TBI was similar for younger and older patients. 25 However, the difference between patients with and without TBI exposure was not evident among those more than 10 years of age.
A recent large study concerning chronic GVHD and its therapy reported the risk of solid cancers, particularly squamous cell carcinomas of the buccal cavity and skin. 26 In our study, the most significant risk for specific types of secondary solid tumors was to patients with squamous cell carcinoma of the oral cavity and esophagus, which in this study was found to be 44-and 22-fold higher than that expected in the general population, respectively. All 10 patients with these cancers had chronic GVHD, eight of whom had the extensive type. Although the most common types of secondary malignancy are epithelial in origin, 1 cutaneous cancers were encountered most frequently among patients in Western countries. This discrepancy may be partly explained either by the difference in the clinical manifestation of chronic GVHD or by a genetic susceptibility and a gene-environment interaction. On the other hand, skin involvement of greater than 50% was apparent only in approximately 10% of Japanese patients with chronic GVHD (unpublished data by NBMTG), whereas in the data of Akpek et al, 27 44% of patients presented with extensive skin involvement, indicating that the incidence of skin cancer is much lower among the Japanese population. Gastric cancer, on the other hand, is the most prevalent neoplasm in Japan, accounting for onequarter of all cancers. [9] [10] [11] [12] In our study, only two cases of gastric cancer were observed after HSCT, an incidence not statistically different from that in the general population. This indicates the existence of a distinctive mechanism underlying the development of post-transplant secondary cancers.
Patients with chronic GVHD, having received immunosuppressive agents over a long period, exhibit persistent inflammation in the involved organs. GVHD may stimulate regeneration of the epithelium and a subsequent overgrowth of malignant cells. Alternatively, prolonged immune suppression may compromise immune surveillance and exert a cocarcinogenic effect on the genetic damage caused by chemoradiation. Host defenses and inflammatory gene polymorphisms may be associated with an increased risk of GVHD, 28 and may also play a role together with DNA repair in solid tumors. In immunosuppressed patients, oncogenic viruses such as human papilloma viruses may contribute to squamous cell carcinoma of the cervix and skin. [29] [30] [31] [32] In our study, two patients developed cervical cancer with an increased risk of 8.6 of RR.
The magnitude of the increased risk of solid tumors after autologous HSCT has been reported to be approximately two-fold when compared to that in an age-and sexmatched general population. 33 A 5-year cumulative incidence of 8.9% was reported for autologous HSCT patients treated for Hodgkin's disease, which was more frequent than that for conventionally treated patients. 34 Four patients developed secondary cancers after autologous transplantation in our study. However, no significant risk factor was detected for the autologous transplantation on multivariate analysis (data not shown). The predominance of cancers of epithelial origin was not observed in our autologous patients. The carcinogenic process may differ from that in the setting of allogeneic transplantation. The difference between autologous and allogeneic transplantation may include the type of disease for which both groups were transplanted, chemoradiotherapy prior to transplant and the presence or absence of an immunoresponse. In fact, about 60% of the allogeneic patients received transplantation for myeloid malignagncies, on the other hand, about 85% of autologous transplant patients had nonmyeloid malignancies.
Although the prognosis for secondary malignancies was generally poor, 35, 36 there was one report of four of five patients who survived after undergoing the same therapy used for de novo cancers. 37 In another recent study, the 5-year survival rate of secondary cancers was 44%. 7 The prognosis mostly depends on whether the secondary cancers can be diagnosed early enough to begin the standard therapy appropriate for each cancer. In our study, most of those who received curative care overcame their secondary cancers, resulting in an overall survival rate of 42.8% at 5 years. It is important for all physicians to be alert to the possibility of secondary malignancy after HSCT, and to monitor more closely patients who developed chronic GVHD.
